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Abstract
Background: Accumulating researches have shown that epithelial-mesenchymal transition (EMT) contributes to
tumor metastasis. Leptin, a key adipokine secreted from adipocytes, shapes the tumor microenvironment,
potentiates the migration of breast cancer cells and angiogenesis, and is also involved in EMT. However, the
potential mechanism remains unknown. This study aims to explore the effect of leptin on EMT in breast cancer
cells and the underlying mechanism.
Methods: With the assessment of EMT-associated marker expression in MCF-7, SK-BR-3, and MDA-MB-468 cells, the
effect of leptin on breast cancer cells was analyzed. Besides, an array of pathway inhibitors as well as RNA interference
targeting pyruvate kinase M2 (PKM2) were used to clarify the underlying mechanism of leptin-mediated EMT in vitro
and in vivo.
Results: The results demonstrated that leptin promoted breast cancer cells EMT, visibly activated the PI3K/AKT
signaling pathway, and upregulated PKM2 expression. An antibody against the leptin receptor (anti-ObR) and
the PI3K/AKT signaling pathway inhibitor LY294002 significantly abolished leptin-induced PKM2 expression and
EMT-associated marker expression. SiRNA targeting PKM2 partially abolished leptin-induced migration, invasion,
and EMT-associated marker expression. In vivo xenograft experiments indicated that RNA interference against
PKM2 suppressed breast cancer growth and metastasis.
Conclusions: Our data suggest that leptin promotes EMT in breast cancer cells via the upregulation of PKM2
expression as well as activation of PI3K/AKT signaling pathway, and PKM2 might be one of the key points
and potential targets for breast cancer therapy.
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Background
Breast cancer is a leading cause of cancer death in
women [1]. Accumulating evidence has shown that
obesity is a significant risk and negative prognosis factor
for breast cancer [2]. Adipose tissue plays a crucial role
as an energy storage depot, and currently, there is clear
evidence that adipocytes act as endocrine cells and pro-
duce various biologically active substances, such as
growth factors, cytokines, adipokines and leptin [3, 4]. In
spite of the strongly suggested association between
obesity and breast cancer, the underlying molecular
mechanisms are not known clearly. Previous studies in-
dicate that leptin, one of the adipokines secreted from
adipocytes, is an important factor that links obesity with
breast cancer [1, 5].
Leptin, a 16-kDa single-chain proteohormone
encoded by the LEP gene, is expressed in a variety of
tissues, including placenta, ovaries, mammary epithe-
lium, bone marrow, and lymphoid tissues [6–9].
Leptin acts through specific leptin receptors (ObRs)
and is a key factor in controlling the biological effects
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of food intake, energy balance, immune, and endo-
crine systems, as well as ontogenesis. Most of these
functions are involved in leptin-induced signals which
comprise several pathways triggered by many cyto-
kines (i.e., canonical signaling pathways: JAK2/STAT,
MAPK/ERK, and PI3K/AKT kinase) [10]. Leptin/ObRs
are expressed at low levels in the epithelial cells of
normal human mammary glands, but overexpressed
in breast cancer cells [9, 11, 12].
Recent studies have shown that EMT is a crucial initi-
ator of and a contributor to tumor invasion and migration
[13]. During EMT, cancer cells undergo morphological
changes, such as cell-cell junction dissolution, loss of
apical-basolateral cell polarity, and acquisition of mesen-
chymal marker expression [14]. Snail, Twist and ZEB, and
the important transcription factors of EMT are critical
points in the study the mechanism of EMT. Twist is a
highly conserved transcription factor and involves in
organ development, cell proliferation, differentiation and
tumorigenesis [15, 16], and it is also a major regulator in
EMT and promotes tumor invasion and metastasis [17–19].
Our previous study showed that leptin and interleukin
8(IL-8) induced EMT in breast cancer cells via the
PI3K/AKT signal pathway [20], and this signal path-
way was a significant canonical signaling pathway in
leptin-induced signals. Besides IL-8 which is involved
in leptin-induced EMT, this study has found that
PKM2 is another critical molecule affecting tumor
progression.
Pyruvate kinase (PK) participates in the final rate-limiting
step of glycolysis and catalyzes phosphoenolpyruvate(PEP)
and ADP to pyruvate and ATP [21]. PKM1, PKM2, PKL
and PKR are four isoforms of PK, and they are expressed in
different types of mammalian cells and tissues [22]. PKM2
is expressed during embryonic development, but it is absent
from most adult tissues [23]. There are reports indicating
that PKM2 is overexpressed in malignant cells and plays
the central role not only in metabolic reprogramming but
also in directed regulation of tumor progression, and
PKM2 could promote EMT in colorectal cancer and hepa-
tocellular carcinoma [14, 24, 25].
In this study, the role of PKM2 in leptin-induced EMT
in breast cancer cells is investigated; it is suggested that
leptin promoted EMT in breast cancer cells via the
upregulation of PKM2 expression as well as activation
of PI3K/AKT signaling pathway, and PKM2 might be




The human breast cancer cell lines MCF-7, SK-BR-3 and
MDA-MB-468 were obtained from American Type Culture
Collection and maintained in DMEM supplemented
with 10 % fetal bovine serum (FBS, Gibco). The cells
were cultured at 37 °C in a humidified incubator
with 5 % CO2.
Immunofluorescence analysis
MCF-7, SK-BR-3 and MDA-MB-468 cells were grown
on coverslips. Cells were washed with PBS, fixed with
4 % paraformaldehyde at room temperature for 20 min,
permeabilized with 0.3 % Triton X-100, and blocked
with 5 % goat serum for 30 min. All cells were incubated
overnight at 4 °C with the corresponding primary anti-
bodies(OBR mouse anti-human) in blocking solution,
washed three times with PBS, and incubated for 1 h in
darkness at room temperature with secondary antibodies
(TRITC-conjugated goat anti-mouse). After washing,
nuclei were stained with DAPI for 10 min in darkness at
room temperature, and then washed three times with
PBS and the coverslips were mounted with 95 %
glycerol. Cell fluorescence was examined using a fluores-
cence microscopy (Olympus, Japan).
RNA isolation and quantitative real-time (qRT)-PCR Assay
Total RNA was isolated using Trizol reagent (TAKARA,
Japan) according to the manufacturer’s protocol. RNA was
stored at −80 °C after being eluted with RNase-free water.
RNA concentrations were measured by spectrophotom-
eter and RNA was reversely transcribed to cDNA using
reverse transcription kit (TAKARA, Japan). Real-time
(RT)-PCR was implemented using iTaq Universal SYBR
Green One-step kit (BioRad). Results were normalized to
the endogenous β-actin mRNA. The following primers
were used: PKM2 sense 5’-CCATCCTCTACCGGCCC
GTTG’, PKM2 antisense 5’- CCAGCCACAGGATGTT
CTCGTC-3’, β-actin sense 5’-CCTTCCTGGGCATGGA
GTCCT-3’, β-actin sense 5’-CCTTCCTGGGCATGGAG
TCCT-3’, β-actin antisense 5’- GGAGCAATGATCTTG
ATCTTC-3.
Cell transfection and infection
MCF-7 and SK-BR-3 were placed in 6-well plates at 2 × 105
per well. Twenty-four hours after placing, siRNA against
PKM2 and negative miRNA (GenePharma, Shanghai) were
transfected to the cells using lipofectamine 2000 liposomes
(Invitrogen) according to the manufacturer’s protocol. After
culturing for 48 h, transfection efficiency was quantified by
Western blotting. The sequences of siRNAs were as
follows: PKM2 sense 5’- CAUCUACCACUUGCAA
UUATT-3’, anti-sense 5’- UAAUUGCAAGUGGUAGA
UGTT-3’; negative control sense 5’-UUCUCCGAACGU
GUACGUTT’, anti-sense 5’- ACGUGACACGUUCGGA
GAATT-3’. Lentivirus-based short hairpin RNA (shRNA)
vector and lentivirus-based cDNA targeting the PKM2 gene
were constructed by GenePharma (Shanghai, China).
PKM2 shRNA was generated with CATCTACCACTTGC
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AATTA oligonucleotide targeting exon 10 of the PKM2
transcript. Lentiviru vector shRNA was generated with
CATCTACCACTTGCAATTA oligonucleotide. Cells were
selected with puromycin for 14 days at 37 °C after
being infected with lentiviral. The effectiveness of
transfection using lentiviruses in SK-BR-3 cells was
verified by Western blotting.
Western blot
All proteins from cancer cells were subjected to SDS-
PAGE and then transferred to PVDF membrane. Blots
were probed with PKM2, p-PKM2, p-AKT (Ser473), AKT
antibody (Cell Signaling Technologies, USA), OBR anti-
body (Santa, USA), E-cadherin, vimentin, and fibronectin
antibody (Bioword, USA). Membranes were analyzed
using Enhanced Chemiluminescence (ECL) detection
system (VIAGENE, USA).
Wound healing migration and matrigel invasion assays
For wound healing migration assays, cells were seeded
onto 6-well plates. After treatment, the cell mono-
layer was scratched with a pipette tip and then
washed three times to remove the floating cells. Then,
fresh serum-free medium with leptin was added, and
photos were taken at 0, 24, 36 and 72 h using a
microscope (Olympus, Japan). Scratch areas were
measured using image software. For invasion assays,
tumor cells were performed using transwell system
(Millipore, USA) with 8 μm-pore polycarbonate filter
membrane. The chambers were pre-coated with 50 μl
matrigel (1:7 dilution; Sigma, USA). The upper cham-
bers were seeded with 2 × 104 tumor cells in serum-
free medium and the lower chambers were filled with
medium containing 15 % fetal bovine serum as a
chemo-attractant. After being incubated for 24 h, cells
on the interior of upper chamber were scrubbed and
the invading cells in the lower chambers were fixed
with 4 % paraformaldehyde. Then, the polycarbonate
membranes were stained with 0.1 % crystal violet for
10 min at room temperature. The number of invasion
cells in five randomly selected fields under micro-
scope (Olympus, Japan) was counted.
Xenografts of nude mice
Breast cancer cells (5 × 106/per inoculation) were
injected into mammary fat pads of 5-week-old female
nude mice (n = 9/group). Tumor volumes were mea-
sured using calipers, and defined as ab2/2(a: length, b:
width). Mice were sacrificed when 5 weeks of post-
injection, and tumors and lungs were removed, fixed in
4 % formaldehyde, and emdedded in paraffin. Tumor
formation and proteins were detected by H&E staining
and immunohistochemical staining. This study was
approved by the Ethical Committee of Chongqing
Medical University.
Immunohistochemistry
The expression of E-cadherin, vimentin, fibronectin,
Twist and PKM2 in xenografts of nude mice were
determined using immunohistochemistry. After being
deparaffinized, tissue paraffin sections were heat-
treated with citrate buffer (0.01 mol/pH6.0) as an
epitope retrieval protocol. Endogenous peroxidase was
blocked with 3 % H2O2 for 15 min, followed by rins-
ing twice, and then sections were incubated with 5 %
goat serum for 30 min to avoid non-specific binding.
After that, sections were incubated with PKM2 anti-
body (Cell Signaling Technologies, USA), E-cadherin,
vimentin and fibronectin antibody (Bioword, USA)
(1:200 dilution; 5 % BSA) at 4 °C overnight. Subse-
quently, sections were washed with PBS 5 times, and
incubated with HRP-conjugated secondary antibody
(BiYunTian, China) for 1 h. The color was developed
using 3-3’-diaminobenzidine after being washed 5
times with PBS. Counterstaining was performed with
hematoxylin. Finally, sections were dehydrated and
mounted with a neutral resin.
Statistical analysis
All experiments were replicated thrice and data were
expressed as mean ± standard deviation. All statistical
analyses were performed with SPSS 19.0 software.
The statistical significance between each group was
analyzed using Student’s t-test or one-way ANOVA.
P < 0.05 was considered as statistically significant.
Results
Leptin exposure induced EMT in breast cancer cells
Leptin must bind specific Ob-R receptors to elicit
biological functions [10]. The expression of long
(Ob-Rb) and short (Ob-Rt) leptin receptor isoforms was
evaluated in MCF-7, SK-BR-3 and MDA-MB-468 cells.
Western blot analysis indicated that both Ob-Rb and
Ob-Rt were expressed in these cells (Fig. 1a), which was
also investigated with immunofluorescence (Fig. 1b). In
addition, these cell morphological changes such as cell-
cell junction dissolution and loss of apical-basolateral
cell polarity were revealed after treatment with
200 ng/mL leptin (Fig. 1c). To further demonstrate
the expression the mesenchymal markers, vimentin
and fibronectin, as well as the epithelial marker,
E-cadherin, were assessed. As shown in Fig. 1d, leptin
upregulated vimentin and fibronectin expression,
while downregulating E-cadherin expression in MCF-7,
SK-BR-3, and MDA-MB-468 cells. Totally, these findings
suggested that leptin could induce MCF-7, SK-BR-3 and
MDA-MB-468 cells EMT.
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Leptin resulted in the upregulation of PKM2 in breast
cancer cells
Serum-starved MCF-7 and SK-BR-3 cells were exposed
to leptin, with the concentration ranging from 50 ng/mL
to 200 ng/mL, or 200 ng/mL leptin for 0 h to 24 h.
PKM2 mRNA and protein expression were detected by
real-time fluorescent quantitative-PCR and Western
blot, respectively. It was found that there was a signifi-
cant increase in PKM2 mRNA and protein expression in
a dose- and time-dependent manner (Fig. 2). PKM2
mRNA and protein expression peaked after 200 ng/mL
leptin treatment (Fig. 2a, b, e–f ) in MCF-7 and SK-BR-3
cells. Therefore, the concentration of leptin at 200 ng/mL
was used for the following experiments.
PKM2 was essential for leptin-induced EMT in MCF-7 and
SK-BR-3 cells
To investigate the effects of PKM2 and leptin on the mi-
gration and invasion of MCF-7 and SK-BR-3 cells,
scratch and invasion assays were performed after treat-
ment with 200 ng/mL leptin and PKM2-siRNA. As shown
in Fig. 3a–d, 200 ng/mL leptin markedly promoted the
migration and invasion of MCF-7 and SK-BR-3 cells.
However, treatment with PKM2-siRNA abolished leptin-
induced migration and invasion. Furthermore, the expres-
sions of EMT-associated molecular biomarkers and EMT
transcription factor, Twist were also determined. Data
showed that leptin upregulated vimentin, fibronectin and
Twist expression, but downregulated E-cadherin expres-
sion. Notably, this effect was weakened after the addition
of PKM2-siRNA (Fig. 3e). These findings indicated that
PKM2 had an effect on the upregulation of Twist, and it
was also essential for leptin-induced EMT in MCF-7 and
SK-BR-3 cells.
PI3K pathway was involved in leptin-induced EMT and
PKM2 expression
To explore the signaling pathways involved in leptin-
induced breast cancer cells EMT, canonical signaling
pathways inhibitors, PD98059, AG490 and LY294002
were used to pretreat serum-starved MCF-7 and SK-BR-3
cells for 1 h, and then treated by 200 ng/mL leptin for
Fig. 1 Leptin promoted epithelial-mesenchymal transition in breast cancer cell lines. a Western blotting analysis with specific antibodies demonstrated
that Ob-Rb and Ob-Rt were expressed in MCF-7, SK-BR-3, and MDA-MB-468 cells. b An immunofluorescence assay showed leptin receptor expression
on the membrane of breast cancer cells. Original magnification: ×400 c Morphological changes of breast cancer cells treated with leptin. The image
showed cell-cell junction dissolution and loss of apical-basolateral cell polarity in MCF-7, SK-BR-3, and MDA-MB-468 cells after treatment with 200 ng/mL
leptin. Original magnification: ×200 dWestern blotting analysis demonstrated that leptin treatment upregulated vimentin and fibronectin expression, but
downregulated E-cadherin expression in MCF-7, SK-BR-3, and MDA-MB-468 cells. All images were representative examples from three
independent experiments
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24 h. As shown in Fig. 4a, the leptin-induced upregulation
of PKM2 was partially abolished by LY294002 (PI3K/AKT
inhibitor), while there was no significant difference when
using PD98059 (MAPK inhibitor) or AG490 (STAT3
inhibitor). Besides, the cells were treated with ObR block-
ing antibodies (4 μg/mL), and then it was found that the
expressions of leptin-induced p-AKT, p-PKM2 and PKM2
were abolished by anti-ObR antibodies (Fig. 4b). These
findings indicated that PI3K pathway was activated after
leptin and ObR binding, which resulted in the overexpres-
sion of p-AKT, p-PKM2 and PKM2. Furthermore, EMT
biomarker and PKM2 were detected after the addition of
LY294002; it was demonstrated that leptin increased
vimentin, fibronectin, p-PKM2 and PKM2 expression but
downregulated E-cadherin expression, and this effect was
reduced by treatment with LY294002 (Fig. 4c). These data
indicated that PI3K pathway was involved in leptin-
induced EMTand PKM2 expression.
RNA interference against PKM2 suppressed tumor growth
and metastasis in xenograft-bearing mouse models
To further investigate the role of PKM2 expression in
tumor growth in vivo, SKBR-3, SKBR-3-shLV, and
SKBR-3-shPKM2 cells were injected into the mammary
fat pads of 5-week-old female nude mice. Within 35 days,
the average tumor volume of SKBR-3-shPKM2 group
was smaller than that of the SKBR-3 and SKBR-3-shLV
groups (Fig. 5a and b), and there was no difference in
tumor volume between the SKBR-3 and SKBR-3-shLV
group. At day 35, mice from each group were sacrificed,
and tumor tissue was surgically removed; SKBR-3-
shPKM2 treatment resulted in a distinct decrease in
Fig. 2 Leptin increased PKM2 expression. (a–f) Serum-starved MCF-7 and SK-BR-3 cells were exposed to concentrations of leptin ranged from
50 ng/mL to 200 ng/mL or 200 ng/mL leptin for 0 h to 24 h. Q-PCR and Western blotting analysis demonstrated that leptin promoted PKM2
mRNA and protein expression in a dose- and time-dependent manner in MCF-7 and SK-BR-3 cells
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tumor size, compared to the size of tumor in the SKBR-3
and SKBR-3-shLV groups (Fig. 5c). In addition, none of the
mice survived for 63 days in SKBR-3 and SKBR-3-shLV
groups, while 50 % of the mice in SKBR-3-shPKM2 group
survived (Fig. 5d). Immunohistochemistry staining was
performed to detect E-cadherin, vimentin, fibronectin and
Twist expression. As shown in Fig. 5e, the expression of
E-cadherin was increased in the SKBR-3-shPKM2 group,
while vimentin, fibronectin and Twist expression were
decreased, compared with SKBR-3 and SKBR-3-shLV
groups. H&E staining showed SKBR-3-shPKM2 resulted in
the reduced lung metastases, compared with SKBR-3 and
SKBR-3-shLV groups (Fig. 5f). Our data showed that RNA
interference against PKM2 suppressed tumor growth and
metastasis in xenograft-bearing mouse models.
Discussion
Epithelial-mesenchymal transition (EMT) has been im-
plicated in tumor cells invasion, metastasis, apoptosis,
stemness and treatment failure [26, 27]. Leptin, an estab-
lished risk factor for many cancers, has been found to
act in the cell cycle, proliferation, tumor development, and
progression [28–30]. Our previous studies demonstrated
that leptin could promote EMT in breast cancer cells [20],
and IL-8 was one of the key molecules which affected
leptin-mediated EMT. To explore other key regulatory
molecules that are involved in leptin-induced EMT of
breast cancer cells, gene expression chip array was con-
ducted, which found that a series of enzymes related to
glycometabolism increased in breast cancer cells, such as
PGK1, PGAM2, PDK2, SUCLG1, DLST, and PKM2. As
one of the most increased molecules, PKM2 was verified to
increase significantly in MCF-7 and SK-BR-3 cells treated
with leptin. Thereby, we hypothesized that leptin promoted
epithelial-mesenchymal transition of breast cancer cells via
the upregulation of pyruvate kinase M2.
Pyruvate kinase M2 (PKM2), which is a key enzyme of
glycometabolism and can act as a transcriptional co-
activator, is overexpressed in multiple cancer types and
involved in the Warburg effect [31–33]. Studies have
shown that PKM2 controls chromosome segregation,
cell-cycle progression, cells proliferation, EMT, and
tumorigenesis [34–36]. It is firstly revealed in this study
that leptin not only induces breast cancer cells EMT, but
also upregulates PKM2 expression; however, the under-
lying mechanism remains unknown.
Fig. 3 PKM2-siRNA abolished leptin-induced epithelial-mesenchymal transition in breast cancer cells. PKM2-siRNA treatment of MCF-7 and SK-BR-3
cells prior to 200 ng/mL leptin exposure decreased leptin-induced migration (a) and invasion (b–d) (P < 0.05). (e) PKM2-siRNA abolished leptin-induced
downregulation of E-cadherin and upregulation of vimentin, fibronectin and Twist in MCF-7 and SK-BR-3 cells (P < 0.05)
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To this end, firstly, canonical signaling pathways inhibi-
tors, PD98059, AG490 and LY294002, were adopted to ex-
plore the signaling pathways involved in leptin-induced
breast cancer cells EMT. It was found that LY294002
blocked leptin-induced PKM2, p-PKM2, p-AKT as well as
EMT-associated marker expression in MCF-7 and SK-BR-3
cells. As reported in other studies, our results also in-
dicated that PI3K/AKT signaling pathway was in-
volved in EMT [37, 38]. In addition, siPKM2
abolished EMT-associated marker expression and
inhibited leptin-induced migration and invasion of
those breast cancer cells. So it strongly suggested that
Fig. 4 Leptin increased PKM2 expression and induced EMT in breast cancer cells via the activation of PI3K/AKT. a Serum-starved MCF-7 and SK-BR-3
cells were treated with PD98059 (MAPK inhibitor, 1.34 μmol/mL), AG490 (STAT3 inhibitor, 5 μmol/mL) and LY294002 (PI3K inhibitor, 10 μmol/mL) for
1 h, followed by 200 ng/mL leptin treatment for 24 h. DMSO was used as a control. Western blotting analysis demonstrated that the PI3K inhibitor
LY294002 abolished leptin-mediated increase in PKM2 expression in MCF-7 and SK-BR-3 cells (P < 0.05). b Antibodies against ObR (4 μg/mL) abolished
the leptin-mediated increase in p-AKT, p-PKM2 and PKM2 expression in MCF-7 and SK-BR-3 cells (P < 0.05). c The PI3K inhibitor LY294002 abolished
leptin-mediated downregulation of E-cadherin expression and the upregulation of vimentin, fibronectin, p-PKM2 and PKM2 expression in MCF-7 and
SK-BR-3 cells
Wei et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:166 Page 7 of 10
leptin could upregulate PKM2 in MCF-7 and SK-BR-3
cells, and PKM2 played a significant role in EMT
induction. It is well known that PKM2 also functions
as a transcriptional coactivator, and the regulatory
mechanism between PI3K/AKT pathway and PKM2
molecular should be elucidated in further researches.
Fig. 5 RNA interference against PKM2 inhibited tumor progression in nude mice. SKBR-3, SKBR-3-LV, and SKBR-3-shPKM2 tumor cells (5 × 106 cells/per
inoculation) were injected into mammary fat pads of 5-week-old female nude mice (n = 9/group). Tumor volumes were measured using calipers and
defined as ab2/2, where a and b corresponded to length and width, respectively. A cohort of mice was sacrificed 5 weeks after injection. (a, b, c) Tumor
volume and primary weights of mice in the SKBR-3-shPKM2 group were significantly smaller than that of mice in the SKBR-3 and SKBR-3-LV groups
(P < 0.01). (d) A survival curve revealed that RNA interference against PKM2 increased the survival of tumor-bearing mice, compared with mice in the
SKBR-3 and SKBR-3-LV groups (P < 0.01). (e–f) H&E staining demonstrated that RNA interference against PKM2 inhibited lung metastasis
of breast cancer xenografts. Immunohistochemistry staining demonstrated that RNA interference against PKM2 resulted in the increased
expression of E-cadherin and decreased expression of vimentin, fibronectin and Twist
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It has been reported that Twist is the key transcrip-
tional factor by down-regulating E-cadherin to promote
EMT, cell motility and invasiveness [17, 39]. In addition,
increased Twist expression is found in multiple tumors
including melanoma [40], prostate [39], pediatric osteo-
sarcoma [41], gastric [42] and breast cancer [17, 43].
The overexpression of Twist positively correlates with
tumor aggressiveness and poor prognosis [17, 39, 40].
Therefore, Twist was detected during EMT of MCF-7
and SK-BR-3 cells induced by leptin, and our data
showed that leptin upregulated Twist expression, but
this effect was weakened by PKM2-siRNA. The potential
mechanism in the interaction of PKM2 with Twist needs
to be studied.
Xenograft-bearing mouse models showed that RNA
interference against PKM2 obviously decreased tumor
volume and weight, increased the survival rate of mice,
and weakened liver and lung metastases. Besides, the
decreased expression of EMT associated markers and
Twist were found by IHC staining of tumor tissue.
Conclusions
This study found that leptin didn’t only induce breast
cancer cells EMT, but also upregulated PKM2 expres-
sion, which resulted from the activation of PI3K/AKT
pathway. Our findings also indicated the crucial role of
PKM2 in leptin-mediated EMT, and PKM2 might be
one of the key points and potential targets for breast
cancer therapy.
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